These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 16296790)

  • 1. Novel hydrofluoroalkane suspension formulations for respiratory drug delivery.
    Rogueda P
    Expert Opin Drug Deliv; 2005 Jul; 2(4):625-38. PubMed ID: 16296790
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel formulation technique for metered dose inhaler (MDI) suspensions.
    Steckel H; Wehle S
    Int J Pharm; 2004 Oct; 284(1-2):75-82. PubMed ID: 15454299
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the molecular interactions in a pMDI formulation by atomic force microscopy.
    Ashayer R; Luckham PF; Manimaaran S; Rogueda P
    Eur J Pharm Sci; 2004 Mar; 21(4):533-43. PubMed ID: 14998585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-pressure aerosol suspensions--a novel laser diffraction particle sizing system for hydrofluoroalkane pressurised metered dose inhalers.
    Jones SA; Martin GP; Brown MB
    Int J Pharm; 2005 Sep; 302(1-2):154-65. PubMed ID: 16102928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system.
    Chattopadhyay P; Shekunov BY; Yim D; Cipolla D; Boyd B; Farr S
    Adv Drug Deliv Rev; 2007 Jul; 59(6):444-53. PubMed ID: 17582648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The nanoscale in pulmonary delivery. Part 2: formulation platforms.
    Rogueda PG; Traini D
    Expert Opin Drug Deliv; 2007 Nov; 4(6):607-20. PubMed ID: 17970664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle formulations in pulmonary drug delivery.
    Bailey MM; Berkland CJ
    Med Res Rev; 2009 Jan; 29(1):196-212. PubMed ID: 18958847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Solvation in hydrofluoroalkanes: How can ethanol help?
    Conti DS; Grashik J; Yang L; Wu L; da Rocha SR
    J Pharm Pharmacol; 2012 Sep; 64(9):1236-44. PubMed ID: 22881436
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Engineering novel topical foams using hydrofluroalkane emulsions stabilised with pluronic surfactants.
    Zhao Y; Brown MB; Jones SA
    Eur J Pharm Sci; 2009 Jun; 37(3-4):370-7. PubMed ID: 19491028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Supercritical fluid technology for enhanced drug delivery.
    Pathak P; Meziani MJ; Sun YP
    Expert Opin Drug Deliv; 2005 Jul; 2(4):747-61. PubMed ID: 16296799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How can we bring high drug doses to the lung?
    Claus S; Weiler C; Schiewe J; Friess W
    Eur J Pharm Biopharm; 2014 Jan; 86(1):1-6. PubMed ID: 24300444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nano-salbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions.
    Bhavna ; Ahmad FJ; Mittal G; Jain GK; Malhotra G; Khar RK; Bhatnagar A
    Eur J Pharm Biopharm; 2009 Feb; 71(2):282-91. PubMed ID: 18984050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of nanoparticles for the treatment of lung diseases.
    Azarmi S; Roa WH; Löbenberg R
    Adv Drug Deliv Rev; 2008 May; 60(8):863-75. PubMed ID: 18308418
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulmonary vaccine delivery.
    Lu D; Hickey AJ
    Expert Rev Vaccines; 2007 Apr; 6(2):213-26. PubMed ID: 17408371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Investigation into the influence of polymeric stabilizing excipients on inter-particulate forces in pressurised metered dose inhalers.
    Traini D; Young PM; Rogueda P; Price R
    Int J Pharm; 2006 Aug; 320(1-2):58-63. PubMed ID: 16735100
    [TBL] [Abstract][Full Text] [Related]  

  • 17. What can we learn from atomic force microscopy adhesion measurements with single drug particles?
    Roberts CJ
    Eur J Pharm Sci; 2005 Feb; 24(2-3):153-7. PubMed ID: 15661486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nanoparticles for drug delivery to the lungs.
    Sung JC; Pulliam BL; Edwards DA
    Trends Biotechnol; 2007 Dec; 25(12):563-70. PubMed ID: 17997181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Twenty years of HFA pMDI patents: facts and perspectives.
    Rogueda P; Lallement A; Traini D; Iliev I; Young PM
    J Pharm Pharmacol; 2012 Sep; 64(9):1209-16. PubMed ID: 22881434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nanoscale in pulmonary delivery. Part 1: deposition, fate, toxicology and effects.
    Rogueda PG; Traini D
    Expert Opin Drug Deliv; 2007 Nov; 4(6):595-606. PubMed ID: 17970663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.